Novartis Ag

Sven Weiler

Nikolaus Johannes Stiefl

Dimitrios Lizos

Thomas Ullrich

Luca Arista

Leo Widler

Michael Patrick Dillon

Marc Gerspacher

Rita Ramos

Tingying Zhu

Benoit Hornsperger

Rainer Albert

Liladhar Murlidhar Waykole

Peggy Usselmann

Michael David Shultz

Jean-Michel Rene Rondeau

Lv Liao

Ruben Alberto Tommasi

Eva Altmann

Leslie Wighton McQuire

Mika Lindvall

Catherine LeBlanc

Nigel Graham Cooke

Xiaoyang Wang

Rene Lattmann

Kai Cui

Yizong Zhou

Yubo Zhang

Jialiang Li

Sreehari Babu

Jianwei Bian

Johanne Renaud

Rene Beerli

Sylvie Chamoin

Olivier Rogel

Duncan Shaw

Simona Cotesta

Wolfgang Jahnke

Vikki Furminger

Sarah Lewis

Cathy Ritchie

Sylvie Teixeira-Fouchard

Barbara Nuesslein-Hildesheim

René Beerli

Jean Michel Rondeau

Pier Luca D'Alessandro

Dimitros Lizos

Pier Luca D'alessandro

Catherine Leblanc

The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Aminopyridine derivatives and their use as selective ALK-2 inhibitors

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 

Pyridinone derivatives and their use as selective ALK-2 inhibitors

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. 

The present invention provides a compound of formula (I): said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).

Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors

A compound of formula (1): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable. 

Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives

Use of compound of formula (I), wherein, is, or, and wherein the symbols are as defined, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, for the preparation of a medicament for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable. 

Quinazoline derivatives which promote the release of parathyroid hormone

Compounds of formula I: in free or salt or solvate form, where R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis. 

Organic compounds

Compounds of formula I in free or salt or solvate form, where R1, R2 and R5 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein R1-R7 are as disclosed in the specification.

Benzimidazole derivatives

C-C-Alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula I, wherein one of Rand Ris hydrogen and the other is C-C-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.

[object Object]

A compound of formula (I): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable. 

Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives

Growing community of inventors

Lörrach, Germany

Sven Weiler